• HOME |
  • SITE MAP |
Product Search


  • Introduction of R&D
  • News of R&D
    • Radiopharmaceuticals
    • New Quinolone Antibiotic
    • Diabetic nephropathy
    • Allergic rhinitis
    • Treatment for Schizophrenia
  • Brief History & Achivement
  • Organization & Operation
  • Major Focused Research
  • The Main Projects
  • Cooperation Research System
  • Technical Cooperation

News of R&D

A new quinolone antibiotic

1. Name of product

Zrumgil (zabofloxacin)

2. Potential advantages

1) More active than any other Quinolones (in vitro, in vivo)

2) Highly active against respiratory tract pathogen (G(+) - S.pneumoniae, S.aureus, S.pyogenes and M.catarrhalis)

3) Good safety profile (in mouse, rat and dog)

4) No phototoxicity

3. Characteristics

New fluoroquinolone antimicrobial agents(Zabofloxacin, DW224) has broad antibacterial activities. It has also excellent activities against RTI pathogen. In preclinical and clinical studies, it has established a good safety profile.

4. Progress

Final stage of phase III clinical trial

Go to TOP

Dong Wha Pharm.CO.,LTD. 19F, STX Namsan Tower, 98, Huam-ro, Jung-gu, Seoul, KOREA

Coptright(c) Dong Wha PHARM.CO.,LTD. All Rights Reserved.